Proteomics and genetics aspects of aspirin resistance

被引:0
作者
Mateos-Caceres, P. J. [1 ]
Azcona, L. [1 ]
Fernandez-Ortiz, A. [2 ]
Sacristan, D. [1 ]
Bernardo, E. [2 ]
Ramos-Mozo, P. [1 ]
Alonso-Orgaz, S. [1 ]
Fernandez-Arquero, M. [3 ]
Lopez-Farre, A. [1 ]
Macaya, C. [1 ,2 ]
机构
[1] Hosp Clin San Carlos, Unidad Invest Cardiovasc, Profesor Martin Lagos S-N, Madrid 28040, Spain
[2] Hosp Clin San Carlos, Unidad Coronaria, Madrid, Spain
[3] Hosp Clin San Carlos, Inst Cardiovasc, Dept Inmunol, Madrid, Spain
来源
TRAUMA-SPAIN | 2008年 / 19卷 / 03期
关键词
Aspirin resistance; proteomics; genetic polymorphisms;
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Aim: To evaluate the existence of a possible association between Aspirin resistance (AR), COX-1 single-nucleotide polymorphisms (SNPs) and the modifications in the plasma proteome of clinically stable coronary patients. Materials and methods: AR was defined according to the PFA-100 assay. AR-sensitive and AR-resistant patients had been taken aspirin for the last 9 months. The proteomic study (19 AR-sensitive, 19 AR-resistant) was performed using IPG strips (17cm, pH 4-7), SDS-PAGE gels (10%) and silver staining. We study three SNPs (A842G, C22T y C50T) in 50 AR-sensitive patients, 33 AR-resistant and 83 controls using a real-time PCR. Results: The expression of four .1-antitripsin isoforms was increased in the aspirin-resistant patients. No differences were found in the expression of ceruloplasmin, haptoglobin-precursor, apolipoprotein-AI and albumin-precursor between both groups of patients. The A-842G SNP was undetectable in all subjects. The remaining two SNPs (C22T y C50T) showed a low frequency with respect the global population. Conclusions: The low SNPs frequencies were unlikely to explain the difference in aspirin responsiveness between both groups of patients. The changes in .1-antitripsin could be linked with a different inflammatory state in these patients.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 50 条
  • [21] Aspirin resistance: Does it exist?
    Rao, Gundu H. R.
    Michiels, Jan Jaques
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (02) : 210 - 214
  • [22] Is aspirin resistance a risk factor?
    Conti, CR
    CLINICAL CARDIOLOGY, 2005, 28 (04) : 163 - 164
  • [23] Aspirin Resistance after CABG
    Sanioglu, S.
    Tetik, S.
    Sokullu, O.
    Deniz, H.
    Aydemir, N.
    Yilmaz, M.
    Arslan, I. Y.
    Bilgen, F.
    THORACIC AND CARDIOVASCULAR SURGEON, 2009, 57 (05) : 281 - 285
  • [24] Aspirin resistance and diabetes mellitus
    R. Ajjan
    R. F. Storey
    P. J. Grant
    Diabetologia, 2008, 51 : 385 - 390
  • [25] A contemporary viewpoint on 'aspirin resistance'
    Kuzniatsova, Nadzeya
    Shantsila, Eduard
    Blann, Andrew
    Lip, Gregory Y. H.
    ANNALS OF MEDICINE, 2012, 44 (08) : 773 - 783
  • [26] The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin
    Al-Azzam, Sayer I.
    Alzoubi, Karem H.
    Khabour, Omar
    Alowidi, Abdallah
    Tawalbeh, Deniz
    ACTA CARDIOLOGICA, 2012, 67 (04) : 445 - 448
  • [27] The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
    Altman R.
    Luciardi H.L.
    Muntaner J.
    Herrera R.N.
    Thrombosis Journal, 2 (1)
  • [28] Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance
    Kim, Jei
    Shin, Byoung-Soo
    Kim, Dae-Hyun
    Shin, Dong-Ick
    Ahn, Seong Hwan
    Kim, Jae Guk
    Ryu, Su Hyun
    Moon, Hye Rin
    Kang, Hyun Goo
    Jeong, Hyeseon
    Yum, Kyu Sun
    Chae, Hee-Yun
    Kim, Do-Hyung
    Kang, Keunsoo
    Kim, Jeeyeon
    BMC MEDICAL GENOMICS, 2024, 17 (01)
  • [29] Reverse genetics for proteomics: From proteomic discovery to scientific content
    Bauer, M.
    Ueffing, M.
    JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (08) : 1033 - 1040
  • [30] Mapping pathways to drug resistance with proteomics
    Burchmore, Richard
    EXPERT REVIEW OF PROTEOMICS, 2014, 11 (01) : 1 - 3